Economic evaluation of three domestic bevacizumab biosimilars and the original bevacizumab for treating nonsquamous non-small cell lung cancer in china: a cost-effectiveness analysis
Domestic bevacizumab biosimilars are cost-effective alternatives to first-line treatment for nonsquamous NSCLC in China. IBI305 exhibited the most significant cost-effective advantage among the domestic biosimilars.
Authors
- Zhaoshi Bai (ORCID: https://orcid.org/0000-0002-6055-8757)
- Silu Xu (ORCID: https://orcid.org/0000-0002-3318-4219)
- Nan Wu (ORCID: https://orcid.org/0000-0002-3531-1656)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3474-422X)
- Tianqi Zhou
- Ning Cai (ORCID: https://orcid.org/0009-0003-0527-9768)
- Jifu Wei
Institutions
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1186/s12962-025-00653-5
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Jiangsu Commission of Health
- China International Medical Foundation